CRON Cronos (CRON) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001656472
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
68
13F, latest reported quarter
Conversions, 180 days
9
Codes C/M, not in net · $0 priced
Cronos insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Cronos Group Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 48 earlier Form 4 trades (code P or S) here by this insider (48 buys), the last on May 25, 2023.
- -28.3% median (-21.0% mean) 90-day return after 24 previous buys.
- The trade is 1.9% of the 601,016 shares held after it.
- No other insider bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ADLER JASON MARC bought about $19.6K of CRON on May 30, 2023; 68 funds added in the latest 13F quarter.Context
- 48 earlier Form 4 trades (code P or S) here by this insider (48 buys), the last on May 25, 2023.
- -28.3% median (-21.0% mean) 90-day return after 24 previous buys.
- The trade is 1.9% of the 1,402,304 shares held after it.
- No other insider bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ADLER JASON MARC bought about $45.7K of CRON on May 30, 2023; 68 funds added in the latest 13F quarter.Context
- 46 earlier Form 4 trades (code P or S) here by this insider (46 buys), the last on May 23, 2023.
- -28.7% median (-21.8% mean) 90-day return after 23 previous buys.
- The trade is 5.1% of the 589,766 shares held after it.
- No other insider bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ADLER JASON MARC bought about $54.0K of CRON on May 25, 2023; 68 funds added in the latest 13F quarter.Context
- 46 earlier Form 4 trades (code P or S) here by this insider (46 buys), the last on May 23, 2023.
- -28.7% median (-21.8% mean) 90-day return after 23 previous buys.
- The trade is 5.1% of the 1,376,054 shares held after it.
- No other insider bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ADLER JASON MARC bought about $126.0K of CRON on May 25, 2023; 68 funds added in the latest 13F quarter.Context
- 44 earlier Form 4 trades (code P or S) here by this insider (44 buys), the last on May 19, 2023.
- -28.7% median (-22.6% mean) 90-day return after 22 previous buys.
- The trade is 5.4% of the 559,765 shares held after it.
- No other insider bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ADLER JASON MARC bought about $57.0K of CRON on May 23, 2023; 68 funds added in the latest 13F quarter.50 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
68 funds bought in last quarter
more than 55% of Pharma & Biotech
Revenue
+24.6% year over year
more than 70% of Pharma & Biotech
Margin
-6.4% net margin
more than 67% of Pharma & Biotech
Buybacks
$32.9M repurchased, FY to 2026-06-30
below 51% of Pharma & Biotech
Short interest
1.8% of the float short (float per yahoo 2026-10-26) · 3.8 days to cover · settled 2026-09-30
below 74% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CRON
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+33.5%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CRON: institutional holders (13F)
13F holdings, latest reported quarter
8,840,503 sh
$24.6M
7,942,737 sh
$22.1M
3,767,849 sh
$10.5M
3,048,254 sh
$8.5M
1,597,039 sh
$6.3M
Congress trades in CRON
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CRON planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CRON mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Amplify Alternative Harvest ETF
$10.1M position · as of 2026-06-30
9.1%
AdvisorShares Pure Cannabis ETF
$1.3M position · as of 2026-06-30
3.9%
USA Mutuals Vice Fund
$1.3M position · as of 2026-06-30
2.6%
Amplify Seymour Cannabis ETF
$358.5K position · as of 2026-06-30
0.4%
The Canadian Small Company Series
$2.1M position · as of 2026-07-31
0.1%
ACUITAS US MICROCAP FUND
$87.5K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Gorenstein
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.1M
$4.9M
$1.5M
-62%
-89%
2024
$4.2M
$3.9M
$1.1M
-71%
-89%
2023
$3.7M
$2.0M
$1.0M
-70%
-84%
2021
$2.5M
-$4.4M
$1.4M
-44%
-39%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 68 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CRON financials
Revenue growth
+24.6%
XBRL, annual
Net margin
-6.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$236.8M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CRON
| FY Dec 2025 | $193.4M |
| FY Dec 2024 | $161.8M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | $114.5M |
| FY Dec 2021 | $89.5M |
| Jun 2026 | $70.6M |
| Mar 2026 | $59.0M |
| Dec 2025 | $58.4M |
| Sep 2025 | $48.8M |
| Jun 2025 | $44.3M |
| Mar 2025 | $41.9M |
| Dec 2024 | $41.2M |
| Sep 2024 | $46.6M |
At each fiscal year end
Single quarter
Net margin, TTM
+32.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CRON
| FY Dec 2025 | -1.5% |
| FY Dec 2024 | +24.7% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -147.4% |
| FY Dec 2021 | -442.6% |
| Jun 2026 | +45.4% |
| Mar 2026 | +23.3% |
| Dec 2025 | +8.1% |
| Sep 2025 | +53.2% |
| Jun 2025 | -89.7% |
| Mar 2025 | +14.6% |
| Dec 2024 | +103.6% |
| Sep 2024 | +17.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$49.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CRON
| FY Dec 2025 | $149.0K |
| FY Dec 2024 | $6.4M |
| FY Dec 2023 | -$45.3M |
| FY Dec 2022 | -$92.4M |
| FY Dec 2021 | -$164.8M |
| Jun 2026 | $22.3M |
| Mar 2026 | $9.0M |
| Dec 2025 | $9.7M |
| Sep 2025 | $8.8M |
| Jun 2025 | -$1.0M |
| Mar 2025 | -$17.4M |
| Dec 2024 | $4.2M |
| Sep 2024 | $5.2M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity CRON
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt CRON
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+7.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CRON
| FY Dec 2025 | -0.3% |
| FY Dec 2024 | +3.7% |
| FY Dec 2023 | -6.6% |
| FY Dec 2022 | -13.6% |
| FY Dec 2021 | -26.0% |
| Jun 2026 | +7.1% |
| Mar 2026 | +0.4% |
| Dec 2025 | -0.3% |
| Sep 2025 | +3.2% |
| Jun 2025 | +1.6% |
| Mar 2025 | +4.5% |
| Dec 2024 | +3.7% |
| Sep 2024 | -4.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+6.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CRON
| FY Dec 2025 | -0.2% |
| FY Dec 2024 | +3.5% |
| FY Dec 2023 | -6.3% |
| FY Dec 2022 | -12.9% |
| FY Dec 2021 | -23.8% |
| Jun 2026 | +6.5% |
| Mar 2026 | +0.4% |
| Dec 2025 | -0.2% |
| Sep 2025 | +3.0% |
| Jun 2025 | +1.5% |
| Mar 2025 | +4.3% |
| Dec 2024 | +3.5% |
| Sep 2024 | -4.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate -16%, not meaningful
Return on invested capital CRON
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-0.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CRON
| FY Dec 2025 | -1.5% |
| FY Dec 2024 | -6.9% |
| FY Dec 2023 | -7.6% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -19.1% |
| Jun 2026 | -0.2% |
| Mar 2026 | -1.3% |
| Dec 2025 | -1.5% |
| Sep 2025 | -1.9% |
| Jun 2025 | -5.0% |
| Mar 2025 | -5.9% |
| Dec 2024 | -6.9% |
| Sep 2024 | -7.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
16.55x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing CRON
| FY Dec 2025 | n/a |
| FY Dec 2024 | 18.36x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 13.90x |
| Mar 2026 | 251.00x |
| Dec 2025 | n/a |
| Sep 2025 | 25.27x |
| Jun 2025 | 31.83x |
| Mar 2025 | 12.93x |
| Dec 2024 | 18.36x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value CRON
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield CRON
| FY Dec 2025 | +0.0% |
| FY Dec 2024 | +0.8% |
| FY Dec 2023 | -5.7% |
| FY Dec 2022 | -9.6% |
| FY Dec 2021 | -11.3% |
| Jun 2026 | +4.8% |
| Mar 2026 | +2.8% |
| Dec 2025 | +0.0% |
| Sep 2025 | -0.5% |
| Jun 2025 | -1.2% |
| Mar 2025 | -1.0% |
| Dec 2024 | +0.8% |
| Sep 2024 | +2.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.07x
P/E over trailing EPS growth of 233%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing CRON
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.06x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $193.4M | $161.8M | $120.3M | $114.5M |
| Gross profit | $62.8M | $25.2M | $11.9M | $15.4M |
| Operating income | -$17.4M | -$76.5M | -$84.8M | -$111.4M |
| Net income | -$2.9M | $40.0M | -$73.9M | -$168.7M |
| EPS (diluted) | -0.02 | 0.11 | -0.19 | -0.45 |
| Operating cash flow | $25.9M | $18.8M | -$42.8M | -$88.9M |
| Cash | $791.8M | $858.8M | $669.3M | $764.6M |
| Buybacks | $9.7M | $0 | $0 | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
CRON Stock Sonar score 4/7 axes
Find similar shapesCompareCRON ranks highest on profitability (85th percentile) and growth (70th), and lowest on risk and compliance (45th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
